Abstract: Contact allergic reactions to topical corticosteroids are common. Cutaneous hypersensitivity reactions to systemically administered corticosteroids might occur though less frequently. The purpose of this literature review is to examine reported cases of cutaneous reactions to systemically administered corticosteroids. The data are presented considering route of administration, type of drug, type of reaction, and testing results. Corticosteroid classifications, cross-reactions, and allergy testing methods are also discussed. 
ALLERGIC CUTANEOUS REACTIONS TO SYSTEMIC CORTICOSTEROIDS
Corticosteroids are commonly used in dermatology and other medical specialties for their anti-inflammatory and immunosuppressive effects. Cutaneous hypersensitivity reactions to topical corticosteroids are a well established and relatively common phenomenon, with a reported incidence of up to 5% in dermatitis patients. 1, 2 Cutaneous hypersensitivity reactions have also been reported with systemically administered corticosteroids, though much less frequently, especially in light of their widespread usage worldwide.
Cutaneous reactions to corticosteroids are usually delayed hypersensitivity reactions (type IV). 3 These delayed hypersensitivity reactions occur more readily following topical exposure to corticosteroids than via other routes of administration. 4 This appears to be due to the role of epidermal Langerhans cells essential for the presentation of corticosteroid haptens. 5 Immediate hypersensitivity (Type I) reactions have also been reported, generally in the setting of intravenous administrations. The exact mechanism of these reactions is unclear, but an IgE-mediated mechanism is presumed. 3 The intent of this article is to review the various systemic administration routes for corticosteroids, reported allergic cutaneous reactions, the most common offending agents, methods for testing for hypersensitivity, and cross reaction patterns.
Reactions and methods of administration
Corticosteroid therapies are utilized in a multitude of formulations by nearly all fields of medicine. In dermatology, corticosteroids are most commonly used topically. Other medical specialties, however, frequently utilize systemic formulations via oral, inhaled, and injected routes. We reviewed the relevant literature for reports of cutaneous reactions to systemically administered corticosteroids. No doubt there are other reports not captured in this review. Our intent is that the information presented in this article will provide the reader with an overview of the types of allergic cutaneous reactions to systemically administered corticosteroids.
Oral
The most common reactions to orally administered corticosteroids occurred with prednisolone (Table 1) . [6] [7] [8] [9] [10] [11] Allergic reactions were also noted with prednisone, betamethasone, and triamcinolone, though in lesser numbers. [12] [13] [14] [15] [16] The majority of these cutaneous reactions were widespread in their presentations, including generalized dermatitis and urticarial reactions.
Patch testing appears to have been successful as the primary tool for diagnosing allergy to orally administered corticosteroids. Further investigations, such as intradermal testing, may be required and were positive in four of the above cases.
Intramuscular
Triamcinolone acetonide is the most commonly used intramuscular corticosteroid and reactions including generalized rash and urticaria have been reported (Table 2) . [10] [11] [12] [13] [14] [15] [16] [17] In one case, the diagnosis was achieved with patch testing, while the other cases required intradermal testing. Cases of reactions to methylprednisolone and hydrocortisone have also been reported. Patch testing was not, however, performed and the diagnosis was made by intradermal testing.
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Intralesional
Intralesional injection of corticosteroids is a commonly used tool in dermatologic practices for the treatment of keloid scars, psoriasis, acne, and other inflammatory dermatoses.
Triamcinolone is the most commonly used intralesional corticosteroid agent. Two of the reported reactions to intralesional corticosteroids were localized cutaneous reactions, although one report of a generalized reaction, a case of anaphylaxis to triamcinolone, occurred (Table 3) . [20] [21] [22] [23] [24] 
Intravenous
There are numerous reports of reactions to intravenous corticosteroids. [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] Of 12 cases reviewed for reactions to intravenously administered corticosteroids, 10 cases noted anaphylactic or urticarial reactions. [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] The majority of these reactions are reported to occur with methylprednisolone and are immediate hypersensitivity reactions reported as anaphylaxis or acute worsening of preexisting asthma. Examples of these cases are listed (Table 4) . Other reported cutaneous reactions were a pruritic rash and purpura to methylprednisolone and hydrocortisone. In some of the reported cases of reactions to intravenous corticosteroids, allergy testing was not performed.
Inhalation (oral inhalers and nasal inhalers)
Orally inhaled and intranasal steroids, such as budesonide, fluticosone, betamethasone, and mometasone, have become common treatment modalities for asthma and allergic rhinitis. The majority of adverse reactions reported with the use of these medications are localized. These reactions include erythema, dryness, and irritation of the nasal and oral mucosa. Such reactions may also extend to the perioral or perinasal skin and thus present to dermatology.
The three reports we reviewed noted two cases of dermatitis and one case of angioedema. Patch testing successfully diagnosed contact allergy in all three cases (Table 5) . [37] [38] Isaksson et al reviewed 34 patients with a history of side-effects following inhaled corticosteroid use. 39 These reactions included facial rash, epistaxis, urticaria, and pruritus. Of these 34 patients, however, only one patient was found to be positive on patch testing to tixocortol pivalate. This raises the possibility of other possible allergens in inhaled corticosteroids which induce cutaneous hypersensitivity reactions. 
Intra-articular
Both triamcinolone and methylprednisolone are commonly used for intra-articular corticosteroid injections, primarily for arthritis and other inflammatory arthritic disorders. The four reports we reviewed noted generalized reactions such as erythema multiforme-like dermatitis, widespread erythema, and generalized urticaria (Table 6) . Allergies were confirmed in each case by patch testing, and in two of the cases, intradermal testing was also positive.
Classifications of glucocorticosteroids
Corticosteroids have been categorized into four groups (A-D) based on their stereochemistry and molecular configurations. 44 These classifications have been further validated by computer conformational analysis by Lepoittevin et al. 45 A further division of group D into subgroups (D1 and D2) has been proposed by Goosens et al (Table 7) . 46 Examples of members from each group are as follows:
Cross-reactivity of corticosteroids
In addition to hypersensitivity to a specific corticosteroid exposure, patients have been noted to be patch test positive to agents with which they have not been previously exposed. This indicates the presence of cross-reactivity between the primary offending agent and other corticosteroids. The potential for cross-reactivity exists within each of the corticosteroid groups. Cross-reaction between groups has also been observed, though to a lesser extent. 
Cross-reactions between groups: group A and group D2
Corticosteroids from group D2 (hydrocortisone-17-butyrate type) have shown significant crossreactivity with other corticosteroids from within this group, as well as corticosteroids from group A (hydrocortisone type) as well as budesonide from group B. 3 Hydrocortisone-17-butyrate from group D2 is enzymatically converted to hydrocortisone of group A in the skin.
Likewise, methylprednisolone aceponate of group D2 is converted in several steps to methylprednisolone of group A and prednicarbate of group D2 is converted to prednisolone of group A.
Corticosteroids from group D1 (betamethasone dipropionate type) have been shown to have minimal cross-reactivity.
Cross-reactions between groups: group B and group D2
Because of the unique molecular structure of budesonide, it has shown cross-reactivity with corticosteroids of both group B and group D2. Lepoittevin et al. demonstrated budesonide crossreactivity with members of group D2 (hydrocortisone-17-butyrate, prednicarbate, alclometasone dipropionate). 45 Ferguson et al. likewise demonstrat- Testing for systemic corticosteroid hypersensitivity Testing for hypersensitivity to systemic corticosteroids may require patch testing, intradermal testing, or both.
Patch testing
Patch testing is generally an adequate screening tool to evaluate hypersensitivity to topical corticosteroids. Patch testing can detect up to 90% of corticosteroid hypersensitivities by the use of tixocortol pivalate and budesonide. 48, 49 Tixocortol pivalate is an effective screening marker for group A (hydrocortisone type) corticosteroids 50 , while budesonide is an effective marker for group B (triamcinolone acetonide type) corticosteroids. Further studies have recommended that tixocortol pivalate and budesonide be testing in a petrolatum at a concentration of 1% for optimal effect. 51, 52 The recommended concentrations for testing these two markers is controversial. The North American Contact Dermitis Group uses concentrations of tixocortol-21-pivalate 1.0% in petrolatum and budesonide 0.1% in petrolatum.
However, the very nature of the corticosteroids' anti-inflammatory effects can make this problematic. 53 The anti-inflammatory effect of a corticosteroid may mask its own patch-test reaction. In addition, there is no consensus concerning the most effective concentrations and vehicles to be used for patch testing. Concentrations that are insufficient may lead to a false-negative reading, as has been repeatedly demonstrated in cases of subsequent positive intradermal testing. Corticosteroid concentrations that are too high may lead to masking of the hypersensitivity reaction. The use of higher concentrations has been recommended for strongly suspected cases of contact allergy in spite of negative readings at the lower concentration. 52 Patch testing is considered a safe option to evaluate a cutaneous reaction to a systemic medication. 54 This method of re-exposure has not been studied extensively, but is a useful diagnostic tool as supported by the case reported cited in this article. For suspected allergy to systemic corticosteroids, patch testing should be performed initially. If these tests are negative, then consider performing intradermal testing to the suspected corticosteroid.
Intradermal testing
Intradermal testing is also used for the detection of allergic reactions to corticosteroids. This method may be of use in situations where inadequate percutaneous penetration of corticosteroids in patch testing may lead to false-negative results. Metabolism and binding to epidermal cells may, also, play a role in the allergic process. 55 Not all formulations are available for intradermal testing.
Intradermal testing is carried out by an intracutaneous injection of the test formulation with a 0.5 to 1.0 ml tuberculin syringe and 26-or 27-guage needle. A volume of 0.1ml is injected into the superficial dermis of the flexor aspect of the forearm and a superficial bleb of 2 to 3 mm diameter should be obtained. 56 A 0.1ml intradermal injection of normal saline should be used as a control. Results should be read at 15 minutes, day 2, and day 4. A 5 to 10 mm wheal is considered to be a positive result.
Due to the limited availability of sterile commercial corticosteroid products, only a select number can be tested. These include, with their recommended concentrations 47 budesonide 0.025%, dexamethasone 0.4%, hydrocortisone-21-sodium phosphate, methyl-prednisolone 4%, and triamcinolone acetonide 4%. There are no controlled studies to date comparing the above test concentrations or standardized concentrations for intradermal testing available.
Risks involved in the use of intradermal testing include atrophy, risk of sensitization, prolonged reactions, and anaphylactic reactions. Systemic reactions are infrequent but can include anaphylaxis. Some deaths have been reported. Because of the potential for serious systemic reaction, adequate emergency measures need to be present. 56 
Oral provocation
Chew and Maibach performed oral provocation testing on a patient with a history of a generalized maculopapular rash and patch test positivity to multiple corticosteroids. 57 Oral provocations with triamcinolone, methylprednisolone, dexamethasone, and prednisone elicited a maculopapular rash. Rechallenge to the suspected systemic corticosteroid is the most definitive way of diagnosing allergy; however, challenge tests are contraindicated in severe drug reactions.
CONCLUSION
While allergic cutaneous reactions to systemically administered corticosteroids are relatively uncommon, they should be considered as possible causes for hypersensitivity reactions. When hypersensitivity to systemic corticosteroids is suspected, patch and intradermal testing should be performed. Further management of these patients requiring systemic corticosteroids (bullous dermatoses, vasculitis, connective tissue disorders) will necessitate a working knowledge of the different classes of corticosteroids, possible cross-reactions, and alternative corticosteroid choices. Awareness of these issues is important to all clinicians utilizing systemic corticosteroid therapy.
